Oncothyreon (ONTY +16%) is higher today on a rumor that Phase III results of its cancer...
Oncothyreon (ONTY +16%) is higher today on a rumor that Phase III results of its cancer treatment drug Stimuvax are meeting endpoints. The stock has been heavily shorted recently - short interest now averages 2+ days to cover - adding to the stock's volatility.
From other sites
at CNBC.com (Feb 24, 2012)
at CNBC.com (Jun 24, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs